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Abstract: Cardiac development is a complex morphogenetic process initiated as bilateral cardiogenic
mesoderm is specified at both sides of the gastrulating embryo. Soon thereafter, these cardiogenic
cells fuse at the embryonic midline configuring a symmetrical linear cardiac tube. Left/right
bilateral asymmetry is first detected in the forming heart as the cardiac tube bends to the right,
and subsequently, atrial and ventricular chambers develop. Molecular signals emanating from
the node confer distinct left/right signalling pathways that ultimately lead to activation of the
homeobox transcription factor Pitx2 in the left side of distinct embryonic organ anlagen, including
the developing heart. Asymmetric expression of Pitx2 has therefore been reported during different
cardiac developmental stages, and genetic deletion of Pitx2 provided evidence of key regulatory roles
of this transcription factor during cardiogenesis and thus congenital heart diseases. More recently,
impaired Pitx2 function has also been linked to arrhythmogenic processes, providing novel roles in
the adult heart. In this manuscript, we provide a state-of-the-art review of the fundamental roles of
Pitx2 during cardiogenesis, arrhythmogenesis and its contribution to congenital heart diseases.
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1. Introduction to Cardiac Development
Cardiac development is an intricate morphogenetic process involving distinct cell lineages.
The first steps of cardiogenic formation are initiated as bilateral precardiogenic mesoderm becomes
specified [1]. Soon thereafter, the bilateral cardiogenic subpopulations merge at the embryonic midline
configuring a linear cardiac tube [2,3] (Figure 1). At this stage of development, the heart is symmetrical,
but soon thereafter, bilateral asymmetry is established as the cardiac tube bulges on its ventral aspect
and then invariably bends rightward. Prospective embryonic atrial and ventricular chambers become
soon established with a common inlet, atrioventricular canal and outlet segments [1] (Figure 1). These
cardiac regions are progressively derived from distinct cardiogenic cell subpopulations, the first heart
field (FHF) and the second heart field (SHF) (Figure 1). As development proceeds, all cardiac chambers
and segments are separated into systemic and venous components by the formation of a series of
cardiac septa [4]. Inflow tract and atrial chambers are divided into right and left components by the
subsequent formation of the primary and secondary atrial septa [5]. Ventricular chambers are separated
by the coordinated formation of interventricular muscular and membranous septa, and distinct aortic
and pulmonary trunks are divided with the formation of the outflow tract septum [6] (Figure 1).
Defects or minimal delays occurring during these morphogenetic processes lead to severe cardiac
congenital malformations such as double inlet left ventricle (DILV), double outlet right ventricle
(DORV), atrial or atrioventricular septal defects (ASD, AVSD), among others.
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While it is rather simple to ascribe embryonic right and left components to the initial symmetrical
cardiac tube [7], the contribution of the mesoderm originally patterned by the left/right axis to
the developing structures is far more complicated and puzzling, a puzzle that remains to be fully
elucidated. Nonetheless, a clear assumption can be drawn from this evidence, i.e., disruption of












































































Figure 1. (A) Schematic representation of the developing heart delineating distinct developmental
stages and the most prominent transcription factors involved in these morphogenetic processes.
Adapted from Paige et al. [11]; (B) Schematic representation of the molecular left/right signalling
pathway emanating from the node and leading to the activation of the homeobox transcription factor
Pitx2 in the left lateral plate mesoderm (LPM) in chicken and mouse, respectively. Images adapted
from Meyers & Martin [12] and Schlueter and Brand [13]. N, node; NT, notochord; HN, Hensen’s node;
RPM, right lateral plate mesoderm; OFT, outflow tract; V, Ventricle; A, Atria; SV, sinus venosus; RV,
right ventricle; RA, right atrium, LA, left atrium; LV, left ventricle.
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2. Cardiac Regulatory Mechanisms
Over the last decade, our understanding of the molecular regulatory mechanisms underlying
cardiovascular development has greatly advanced. Seminal papers reported key roles of distinct
growth factors [14–16] and transcription factors [17] during early phases of cardiogenesis. Among
those transcription factors, Nkx2.5, Mef2, Gata4 and Srf can be defined as core cardiogenic regulatory
molecules [18] (Figure 1). In fact, reprogramming of skin fibroblasts into cardiomyocyte underlies the
functional importance of some of these transcription factors (Mef2, Gata4) [19,20]. In addition to these
“global” cardiac-enriched transcription factors, a large array of tissue-restricted transcription factors
has been identified during cardiogenesis. Hand1 and Hand2 transcription factors display ventricular
chamber-specific expression in the systemic and venous components [21]. Tbx1 is restricted to the
arterial pole with minimal contribution to the developing myocardial component, but essential for
aortic arch formation and remodelling [22]. Tbx2 is confined to discrete areas of the developing heart,
such as the outflow tract and atrioventricular canal, a pattern rather similar to Tbx3, contributing
thereafter to some of the prospective cardiac conduction system components [23]. Tbx5 is restricted
to the systemic ventricle, as well as both atrial chambers [24,25], whereas Tbx18 is confined to a
discrete subset of ventricular cardiomyocytes, as well as to the venous pole of the heart [23]. Similarly,
the Iroquois family members (Irx1 to Irx6) also display tissue-specific expression and thus functional
roles during cardiogenesis [26–29]. Overall, these data demonstrate a complex orchestration of
temporal and tissue-specific transcriptional regulation during cardiac development.
A particular case is the homeobox transcription factor Pitx2. Pitx2 expression is already present in
the developing embryo soon after gastrulation [30–33]. Pitx2 subsequently acquires a tissue-restricted
pattern in the early symmetrical organ anlages, including the heart, and its expression continues to be
modified as organogenesis takes place, as we will see in the following chapters.
3. The Homeobox Transcription Factor Pitx2
Homeobox genes encode transcription factors that bind to cognate DNA sequences through their
conserved homeodomain regions [34]. Pitx1, Pitx2 and Pitx3 are three vertebrate paralogues from
the Pitx family [35]. The Pitx proteins belong to the bicoid-related subclass of homeodomain proteins
with the lysine residue at position nine of the third helix, being the major determinant of DNA and
RNA binding specificity [36], and are highly conserved at the amino acid level at the C-terminal while
significantly diverging at the N-terminal [35].
The Pitx family is crucial for the formation of several tissues. Pitx1 is involved in development and
specification of a number of structures including first branchial arch derivatives, body wall and hind
limb musculature [37–40], whereas Pitx2 is fundamental to brain, pituitary, facial structures and heart
development [41–46]. Pitx3 is the third gene of the family, and it is central to eye and dopaminergic
neurone development [47–49].
The Pitx2 transcription factor is widely distributed in different species [42] and is encoded by the
Pitx2 gene, which is located on chromosome 3 (3G3; 3 57.84 cM) in the mouse [50]. This transcription
factor displays three different isoforms, which are generated by alternative splicing with a common
promoter for Pitx2a and Pitx2b located upstream of exon 1, whereas Pitx2c uses an alternative promoter
located upstream of exon 4 and a left side-specific enhancer (ASE) upstream of exon 6 [35,43,50–54]
(Figure 2). These three isoforms share exons 5 and 6, but differ in others; exon 3 is Pitx2b specific, while
exon 4 is Pitx2c specific. Different laboratories assessed by genetic and/or epigenetic studies and Pitx2
knockout mice that this gene is required for the proper development of several organs and structures,
such as the pituitary gland, craniofacial region, eyes, heart, abdominal viscera and limbs [30–33,35,
36,43,50,55–58]. In human, PITX2 was identified by positional cloning of the 4q25 locus in patients
with Axenfeld-Rieger syndrome [53]; a syndromic condition coursing with cardiovascular outflow
tract malformations, eye dysmorphogenesis, craniofacial and pituitary abnormalities. Furthermore,
Cox et al. [52] reported a new PITX2 isoform (PITX2D) in humans generated by the PITX2C alternative
promoter and differential splicing, acting as a dominant negative isoform, specifically against PITX2A
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and PITX2C (Figure 2). PITX2 mutations are associated to Axenfeld-Rieger syndrome [53,59–61] and
several cardiac defects, as we will detail below.
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Figure 2. (A) Schematic representation of the Pitx2 genomic structure and the corresponding Pitx2
isoforms in humans and mice; (B) Schematic representation of the Pitx2 isoform (Pitx2b and Pitx2c)
expression patterns during cardiac development.
4. Pitx2 and Left-Right Signalling
During the early steps of gastrulation, the developing mouse and human embryo are symmetrical.
Soon after gastrulation, the first signs of bilateral asymmetry are observed as the developing heart
bulges ventrally and then bends to the right. Genetic analyses have demonstrated that morphological
asymmetry is preceded by molecular asymmetry [62–64], Several molecules have been identified in
different species to be asymmetrically expressed during gastrulation such as lefty-2 in Xenopus and
mice [65–71], Nodal in Amphioxus, Xenopus, zebrafish, rat and mice [72–76], cryptic in mice [77], Charon
in zebrafish [78], Fgf8 and Hh in chicken and mice [79,80], Cerl-2 in mice [81–84] and SnR in chicken [85].
Importantly, several of these asymmetric regulators display left/right differential expression in the
lateral plate mesoderm (LPM), while others already display asymmetric expression in the embryonic
midline left/right organizer (LRO), within the developing node. In fact, differential expression in the
node [86] and directional flow mediated by cilia in the node [87–91] have been extensively reported to
be governing left/right symmetry break. In addition, cell movements within the node have also been
implicated in left/right asymmetry [92]. However, two important conclusions can be drawn from all of
J. Cardiovasc. Dev. Dis. 2017, 4, 16 5 of 19
these datasets; first, the node plays a fundamental role in establishing left/right symmetry break and
particularly node cilia and node cilia-related flow (with some exceptions such as the chick and the pig);
and second, the left/right symmetric break is a conserved morphogenetic process in most vertebrate
phyla having a core signalling cascade represented by nodal > Pitx2 with different variable players in
distinct species (Figure 1). Importantly, Pitx2 is therefore the last effector of the left/right signalling
cascade transmitting positional information from the uncommitted LPM to distinct organ primordia
such as the heart, lung and gut, among others [93–95], leading to distinct sidedness alterations within
these organs if impaired [45,55,96–100].
Thus, the left LPM provides different signals controlling embryonic left-right asymmetry.
Several laboratories have shown that Pitx2 expression is confined to left LPM in chick, frog and
mouse [30–33,56,57], as well as the cardiogenic precursors of the left SHF [101]. During development,
Pitx2 continues to be expressed asymmetrically in several organs. Over-expression studies in Xenopus
and chicken demonstrate that Pitx2 is important in the determination of vertebrate heart and gut
looping [30–33,56,57].
Pitx2 isoforms distinctly contribute to the regulation of left-right asymmetry [99,102,103]. Pitx2a,
Pitx2b and Pitx2c are symmetrically expressed in the head at the beginning of development, but Pitx2c
is only expressed asymmetrically in the LPM from two to four somite stages in the mouse. During
development and adulthood, Pitx2c expression still remains in the developing heart [104–106]
(Figure 2). This expression pattern is highly conserved among species, highlighting the role of
Pitx2 during development [7,33,93,94,107,108]. Experimental models of gain and loss of function
demonstrated that Pitx2 is dispensable in driving looping directionality in mice [32,33,35,43,58,96,109],
contrasting with those findings in other experimental models [30–33,56,57]. To date, such discrepancies
remain to be fully elucidated.
5. Genetics of Congenital Heart Diseases
Congenital heart disease (CHD) is the most prevalent developmental abnormality in humans.
CHD is indeed the most common non-infectious cause of infant morbidity and mortality. Increasing
evidence has demonstrated a crucial contribution of genetic defects in the pathogenesis of CHD.
Mutations in several transcription factors such as HAND1, HAND2, TBX5, GATA4, NKX2.5 and TBX20
have been identified in patients affected with distinct congenital heart diseases, such as atrial septal
defects (TBX5, GATA4, NKX2.5, TBX20), Tetralogy of Fallot (TBX5, TBX20), ventricular septal defects
(HAND2), double outlet right ventricle (HAND1), either syndromic (Holt-Oram; TBX5) or isolated
(see for recent reviews [110,111]). However, CHDs are genetically heterogeneous, and at present,
the genetic determinants of CHD in most patients remain yet unknown. We provide herein current
state-of-the-art evidence on the contribution of the homeobox transcription factor PITX2 as a genetic
determinant of congenital heart diseases.
6. Left-Right Signalling and Congenital Heart Diseases
The adult heart is an asymmetric organ. It is topologically located outside the body midline with
the apex oriented to the left. Morphologically, the atrial chambers are rather similar, but conspicuous
differences, such as the extent of the smooth region and the abundance of the pectinate muscles, provide
hallmarks for distinguishing right and left atrial appendages [6]. Such left/right atrial differences are
more easily assessed if their venous connections are taken into account. In humans, four pulmonary
veins drain into the left atrium, whereas two caval veins (right superior and inferior caval veins) and
the coronary sinus drain into the right atrium. In mice and other rodent species, pulmonary veins
drain with a single orifice in the left atrium, whereas three caval veins drain into the right atrium.
Atrioventricular valves are also left/right asymmetric, as the mitral valve has two leaflets and the
tricuspid valve three. At the arterial pole, including the ventricles, asymmetry is also evident, as the
left ventricle is larger than the right ventricle, and the aortic and pulmonary outlets are displaced
from the body midline [5,112]; yet, these differences do not reflect in most cases embryonic left/right
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differences. Importantly, embryonic left/right contribution to the atria and ventricles is markedly
different as reported by Pitx2 expression [4,7,113].
Several cardiac abnormalities have been classically reported as defects of the establishment of the
left/right body axis (laterality defects). Right atrial isomerism (RAI) is the most common defect in
which the heart is formed by isomeric right atria and impaired venous return connections, displaying
in most cases the absence of direct pulmonary vein drainage to the atria and bilateral caval veins
connections. In this context, both atria display a right-specific pattern; i.e., morphologically right atrial
appendages. Left atrial isomerism (LAI) is rather less frequent, presenting isomeric left atria with the
absence of direct caval vein drainage to the atria and bilateral pulmonary vein connections, i.e., right
pulmonary vein to the right atrium and left pulmonary veins to the left atrium. Similarly LAI also
displays a left-specific pattern in both atria; i.e., with morphologically left atrial appendages. These
cardiac alterations can occur with an impaired left/right topology of all other body organs, a condition
dubbed situs inversus, or not, a condition dubbed situs ambiguus. Several lines of experimental evidence
demonstrated that impaired left/right signalling underlies RAI and LAI.
The plausible contribution of left/right signalling to other congenital heart defects such as double
outlet right ventricle (DORV), double inlet left ventricle (DILV), atrial or atrioventricular septal defects
(ASD and AVSD) remains enigmatic, as well as in syndromic congenital heart defects such as Tetralogy
of Fallot. Thus, an important question is when is cardiac asymmetry established during embryonic
development and which is the particular contribution of left/right cardiac embryonic tissues to the
adult heart. We will provide herein state-of-the-art evidence on the plausible role of left/right signaling,
with particular emphasis on the homeobox transcription factor Pitx2, on the genesis of these cardiac
congenital defects.
7. Pitx2 and Congenital Heart Diseases
Systemic deletion of Pitx2 in experimental models revealed complex embryonic defects. Abnormal
sidedness was observed in distinct developing organs such as the lungs, gut and heart in mice.
Embryonic development was compromised at Embryonic Days (ED) 13–14. Within the cardiovascular
system, Pitx2 null mutants displayed right atrial isomerism with impaired venous return [45,55,58].
Pulmonary vein development was severely impaired as was the sinoatrial node development [114,115].
Isoform-specific deletion of Pitx2c in mice demonstrated that it was mainly this isoform that was
responsible for all of the cardiovascular embryonic defects [116]. Furthermore, conditional deletion
in mice highlighted the importance of Pitx2 driving cardiac left-right asymmetry from the secondary
heart field [117] and opened up the possibility of spatio-temporally-controlled deletion of Pitx2 in
distinct cardiac compartments. Tessari et al. [118] conditionally ablated Pitx2 function in the early
embryonic cardiomyocytes, and surprisingly, right/left cardiac asymmetry was unaltered. Atrial
and ventricular-specific deletion in mouse embryos [104], as well as temporal deletion in postnatal
hearts [118,119], displayed similar findings. Only when Pitx2 deletion was carried out in the nascent
cardiomyocytes, right atrial isomerism was observed [120]. Overall, these data demonstrate a highly
controlled temporal and tissue-specific action of Pitx2 during cardiac development that, if impaired,
can lead to distinct cardiac congenital heart diseases. Therefore, these observations postulate Pitx2 as a
candidate gene for cardiac congenital heart diseases (Figure 3).
CHARGE syndrome is characterized by ocular Coloboma, congenital Heart defects, Atresia of the
choanae, Retarded growth, Genital hypoplasia and Ear anomalies including deafness in the context of
global developmental delay. Initial screening in CHARGE syndrome patients discarded PITX2 as a
causing gene [121]. Subsequent screening in a small cohort of transposition of great arteries (TGA)
patients similarly failed to identify PITX2 causal mutations [122]. More recently, PITX2 point mutations
have been identified in distinct isolated cardiac congenital heart diseases [123], such as atrial septal
defects (ASD) [124], TGA [125], ventricular septal defect (VSD) [125,126] and Tetralogy of Fallot [127].
A PITX2 mutation has also been identified in a patient with compound congenital heart disease (CHD),
i.e., DORV and VSD. In all cases, functional analyses of their corresponding PITX2 mutation leads to
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decreased transcriptional activity and reduced synergistic activation with NKX2.5 [124–127] (Table 1).
Furthermore, point mutations in CITED2, identified in a Tetralogy of Fallot patient with aortic stenosis,
impaired PITX2 and VEGF expression [128], further support a functional role for PITX2 in this type of
CHD. In addition to the identification of PITX2 mutations in isolated CHD, a loss-of-function PITX2
mutation has been identified in an Axenfeld-Rieger syndrome patient carrying cardiac endocardial
cushion defects. Such a PITX2 mutation provides no transcriptional and synergistic activity with
Nkx2.5 [129]. Overall, these data demonstrate a pivotal functional role of PITX2 in cardiac congenital
heart diseases (Figure 3).
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8. Beyond CHD: Pitx2 and Atrial Fibrillation
Atrial fibrillation (AF) is t e most common cause of arrhythmogenesis, and it has been related to
several risk factors, such as advanced age, male gender, hypertension, obesity, ischaemic heart disease,
myocardial infarction, valvular diseases and hyperthyroidism [134–136].
Several genome-wide association studies (GWAS) have been published reporting chromosomal
loci in association with atrial fibrillation (AF). Four different genetic loci on chromosomes 1q21-KCNN3,
4q25-Pitx2, 16q22-ZFHX3 and 16q13-IL6R have been associated with this arrhythmia [137–141]. GWAS
meta-analyses have provided additional risk variants associated with AF, implicating six new loci in AF;
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CAV1, HCN4, SYNE2, SYNPO2L, PRRX1 and WNT8A [140,142,143], but importantly, the most relevant
associated risk variants are those located in the vicinity of the PITX2 locus [104–107,144–147]. Thus,
this seminal GWAS study by Gudbjartsson et al. [137], identifying single nucleotide polymorphisms
(SNPs) at the 4q25 locus, proposed an association between PITX2 and AF, as a causative molecular
link. Thus, a novel role for Pitx2 in the adult heart has therefore emerged.
Distinct laboratories, including ours, have demonstrated that PITX2 potentially regulates AF
through modulation of multiple genes implicated in AF; KCNN3 [140,145,147]; TBX5 [148–150];
HCN4 [145,151]; KCNJ2 [104,152]; CAV-1 [145,147]; KCNQ1 [151,153]; ZFHX3; SYNE2; Il6R [147];
ENPEP [154]. In addition, a transcriptional network that linked AF risk loci has been recently described.
Tbx5 directly activated Pitx2, and Tbx5 and Pitx2 antagonistically regulated membrane effector genes
Scn5a, Gja1, Ryr2, Dsp and Atp2a2 [150] (Table 2).
Genomic regions containing the risk variants have been reported to play a role in Pitx2 regulation
in a tissue- and isoform-specific fashion [154,155], and a functional role for Pitx2 in atrial arrhythmias
using distinct experimental models has been demonstrated [104,152,156]. Experimental studies have
demonstrated that Pitx2 loss of function predisposes to atrial arrhythmogenesis. Mice heterozygous
for Pitx2 are susceptible to AF during programmed stimulation [106]. Pitx2 haploinsufficiency
predisposes to AF in electrically-stimulated adult mice, provoked by ectopic Shox2 expression in
the foetal left atrium (LA), which in turn deregulated other pivotal sino-atrial node genes such as Hcn4
and Tbx3 [105].
Table 2. Summary of distinct signalling pathways regulated by Pitx2 and currently associated with
atrial fibrillation.
Cardiac
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Other substrates for AF are left-sided electrophysiological defects generated by Pitx2 impairment
in atrium-specific conditional Pitx2 mouse mutants [104]. In this model, in foetal and adult stages,
voltage-gated sodium and inward rectifying potassium channels are abnormally expressed in the atrial
myocardium [104]. Moreover, dysregulation of ion channels resulting from impaired Pitx2 dosage
has been reported in adult Pitx2 heterozygous mutant mice [106]. In Pitx2c heterozygous mutant
mice, the expression of TWIK-related acid-sensitive K+ channel (TASK-2) and TASK-like background
currents are reduced, although IK1 is not altered [157]. Impaired gap junction expression in adult
heterozygous Pitx2 mutant mice has been reported [106], being in concordance with the fact that Pitx2
controls Gja5 expression [104,152] and with reports of mutations in gap junctional proteins in the
context of AF ([158]). Surprisingly, chronic AF patients display upregulation of PITX2C, contributing
to IKs increase and ICa,L reduction [159]. While these controversial findings remain to be elucidated,
currently we can conclude that impairing Pitx2 (upregulation or downregulation) is critical for cardiac
electrophysiology and, thus, tightly linked to the onset of cardiac arrhythmias.
Our laboratory recently reported that Pitx2 insufficiency also regulates WNT8 expression, which
modulates a complex gene regulatory network, including multiple microRNAs, with a large impact
on calcium homeostasis control and pro-arrhythmogenic events [147]. Multiple microRNAs are
downstream from Pitx2 and involved in AF. ChiP-sequencing studies have reported that Pitx2
positively regulates miR-17-92 and its related homologue miR-106b-25. Deficient mice in these miRNAs
clusters show arrhythmia susceptibility and dysregulation of Shox2 and Tbx3, similar characteristics to
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Pitx2-deficient mice [151]. IK1 channel expression is modulated by miR-1 [160], which is upregulated
in Pitx2 atrial-deficient mice [104]. A significant number of microRNAs differentially expressed in AF
patients are regulated by Pitx2 and Wnt signalling, such as miR-1, miR-26b, miR-29a, miR-106a/b and
miR-133 [147,161].
However, a question that remains unsolved is whether impaired Pitx2 function already alters
cardiac function during embryogenesis, as suggested by Wang et al. [105], or whether it is mainly
an adulthood deficiency that is causing atrial fibrillation, as suggested by Chinchilla et al. [104].
We demonstrated herein that atrial-specific Pitx2-insufficient embryonic (ED18.5) mice showed
arrhythmogenic substrates already at these early stages in homozygous knockout mutants. These
animals showed prolonged atrial activation time (Figure 4) under the sinus rhythm. Similarly, slower
impulse propagation was noted also in the electrically-stimulated beats, both in the left and right
atrial appendages (Figure 4). Interestingly, there was no significant morphological substrate present
at that point, as the amount of collagen, detected by Picrosirius red staining, was uniformly low and
not different between controls and mutants. Furthermore, connexin43 expression in the atria did
not differ between controls and mutants. These results therefore suggest that functional changes
in atrial-specific Pitx2-insufficient mice pre-date structural differences. We therefore propose herein
a reconciling hypothesis. Pitx2 insufficiency already predisposes from embryonic stages to atrial
electrical impairment in the absence of structural alterations. Onset of spontaneous arrhythmogenic
events might be triggered by additional AF risk factors such atrial dilation [104] or by progressive
Pitx2 downregulation that can course with age and hypertension [162]. Furthermore, the first
arrhythmogenetic events also lead to Pitx2 downregulation, subsequently predisposing to the onset of
additional arrhythmogenetic events [156].
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Figure 4. Optical mapping analyses of embryonic heterozygous (HT) and homozygous (KO)
atrial-specific Pitx2 mutants. Observe that atrial activation times are significantly slower in homozygous
as compared to heterozygous hearts. In addition, right and left atrial pacing, respectively display
similarly slower activation times, demonstrating an inherent electrical difference between heterozygous
(HT) and homozygous (KO) atrial-specific Pitx2 mutants.
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9. Conclusions and Future Perspectives
Congenital heart diseases are multifactorial. Over the last few decades, we have witnessed a
large advance in the understanding of the genetics of congenital heart diseases. Mutations in different
transcription factors have been identified in familial and sporadic cases of distinct congenital heart
diseases. Genetic engineering in mice has further provided additional evidence of the functional role
of these transcription factors (and their corresponding mutations) in CHDs. Herein, we have provided
a state-of-the-art review of the contribution of the homeobox transcription factor Pitx2 to congenital
heart diseases. Pitx2 participates in early embryonic left/right signalling and cardiac embryogenesis,
and it remains to be expressed in the adult heart. Therefore, the contribution of Pitx2 to CHDs might
involve distinct roles at different developmental stages. In this line of thinking, Fakhro et al. [163]
reported a genetic screening of rare copy number variations in heterotaxia patients and identified
genes involved in cilia function. Experimental manipulation of these cilia-related genes led to impaired
Pitx2 expression in Xenopus experimental models, providing functional links between cilia, left/right,
Pitx2 and heterotaxia. Distinct genetic Pitx2 manipulations have also reported distinct congenital heart
diseases, establishing temporal and tissue-specific contributions [117,118,120]. More recently, a link
between Pitx2 and atrial fibrillation has been reported [164–166]. Our data and others demonstrated
that electrical alterations underlying Pitx2 insufficiency are already present at foetal stages, suggesting
therefore a congenital substrate on the future onset of atrial arrhythmogenesis. Thus, whether AF
might be considered as a developmental disease should be debated.
In addition to experimental models demonstrating the functional role of Pitx2 in CHDs, emerging
evidence also identified point mutations associated with distinct CHDs, ranging from isolated atrial
septal defects to complex cases of Tetralogy of Fallot. At present, evidence of the functional role of
these point mutations in these CHDs is rudimentary. CRISPR/Cas9 gene editing of these mutations
might in future shed light on the specific contribution of Pitx2 mutations to CHDs.
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